1025941-26-7

Usage

Appearance

Yellow crystalline solid describes the physical form and color of the compound, which can be helpful in identification and handling.

Melting point

163-165°C the temperature range at which the compound transitions from a solid to a liquid state, which can be important for determining its stability and purity.

Imidazole ring

A five-membered heterocyclic ring containing one nitrogen atom this structural feature contributes to the compound's unique chemical and biological properties.

Nitrophenyl group

A functional group consisting of a phenyl ring with a nitro group (-NO2) attached this group is known for imparting specific biological activities and can influence the compound's pharmacological properties.

Potential applications

Pharmaceutical and organic synthesis the unique chemical structure and biological activities of 1-Imidazol-1-yl-2-(3-nitro-phenoxy)-ethanone make it a valuable building block for creating various compounds with potential applications in these fields.

Versatile building block

The compound's synthesis and properties make it suitable for the preparation of a wide range of compounds with potential biological and pharmacological activities, increasing its importance in chemical research and development.

Upstream product

• 138563-69-6 tert-butyl 2-(3-nitrophenoxy)acetate 
• 554-84-7 meta-nitrophenol 

Downstream Products

• 50508-38-8 4-[(3-nitro-phenoxy)-acetyl]-morpholine 
• 184944-87-4 N-(2-(3-aminophenoxy)acetyl)morpholine 
• 62877-06-9 (3-aminophenoxy)acetamide 
• 90370-49-3 (3-nitrophenoxy)acetamide 

Relevant academic research and scientific papers

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent

Analogs of the previously reported 1,5-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonist 1 were prepared which explore substitution and/or replacement of the C-3 phenyl urea moiety. Agonist efficacy on the isolated guinea pig gallbladder (GPGB) was retained with a variety of substituted ureas and amide analogs. Three compounds were identified which were orally active in the mouse gallbladder emptying assay (MGBE). The 2-indolamide (52) and N-(carboxymethyl)-2-indolamide (54) derivatives had improved affinity for the human CCK-A receptor but reduced agonist efficacy on the GPGB. Neither indolamide was orally active in a rat feeding assay. In contrast, the (3-carboxyphenyl)urea derivative (29, GW7854) had moderately increased affinity for the human CCK-B receptor but was a potent full agonist on the GPGB and was orally active in both the MGBE and rat feeding assays. GW7854 was a full agonist (EC50 = 60 nM) for calcium mobilization on CHO K1 cells expressing hCCK-A receptors and a potent antagonist of CCK-8 (pA2 = 9.1) on CHO K1 cells expressing hCCK-B receptors. GW7854 is a potent mixed CCK-A agonist/CCK-B antagonist which is orally active in two in vivo models of CCK-A-mediated agonist activity.